|
Real-time Estimate
Cboe BZX
12:03:50 03/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 4.505 USD | +1.46% |
|
-4.06% | -30.50% |
| 17/09 | Aquestive Therapeutics Resubmits New Drug Application to FDA for Anaphylm (Dibutepinephrine) Sublingual Film | CI |
| 17/09 | Aquestive Therapeutics Resubmits Anaphylm NDA to FDA | MT |
| Market Cap | 56Cr 50Cr 46Cr 42Cr 79Cr 5.36TCr 80Cr 559.26Cr 216.71Cr 2.74TCr 209.23Cr 204.69Cr 8.79TCr | P/E 2026 * |
-8.71x | P/E 2027 * | -9.25x |
|---|---|---|---|---|---|
| Enterprise Value | 48Cr 43Cr 40Cr 36Cr 68Cr 4.61TCr 69Cr 480.98Cr 186.38Cr 2.36TCr 179.94Cr 176.04Cr 7.56TCr | EV / Sales 2026 * |
9.6x | EV / Sales 2027 * | 8.22x |
| Free-Float |
97.1% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| AQST | Delayed | |
CBOE
| AQST | Real-time |
Last Transcript: Aquestive Therapeutics, Inc.
| 1 day | +1.46% | ||
| 1 week | -4.06% | ||
| Current month | -3.02% | ||
| 1 month | -16.54% | ||
| 3 months | +7.42% | ||
| 6 months | +8.72% | ||
| Current year | -30.50% |
| 1 week | 4.42 |  | 4.78 |
| 1 month | 4.42 | | 5.48 |
| Current year | 2.93 | | 6.59 |
| 1 year | 2.93 | | 7.55 |
| 3 years | 1.25 | | 7.55 |
| 5 years | 0.62 | | 7.55 |
| 10 years | 0.62 | | 20.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel Barber
CEO | Chief Executive Officer | 50 | 17/05/2022 |
A. Toth
DFI | Director of Finance/CFO | 67 | 31/12/2020 |
Thomas Zalewski
CMP | Compliance Officer | - | 02/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Gregory Brown
CHM | Chairman | 72 | 01/04/2024 |
John Cochran
BRD | Director/Board Member | 60 | 01/01/2004 |
Daniel Barber
BRD | Director/Board Member | 50 | 17/05/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/09/26 | Sell | Chief Executive Officer | -25,000 | 0.0199% | ||
| 09/09/26 | Option | Head of Human Resources | 4,586 | 0.0037% | ||
| 09/09/26 | Exercice | Executive/Senior Manager | 26,250 | 0.0209% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.46% | -4.06% | -22.18% | +220.71% | 56Cr | |
| -0.41% | -3.47% | +39.35% | +112.24% | 1,02500Cr | |
| -1.21% | -5.82% | +37.35% | +64.64% | 62TCr | |
| +0.90% | -0.83% | +10.81% | +76.82% | 46TCr | |
| -0.22% | -3.56% | +60.31% | +39.92% | 35TCr | |
| -0.95% | -4.05% | +21.60% | +39.37% | 34TCr | |
| -1.46% | -2.89% | +11.84% | +24.60% | 27TCr | |
| -1.35% | -5.43% | -4.69% | +8.40% | 25TCr | |
| -0.76% | -2.76% | +35.56% | +51.39% | 22TCr | |
| -2.08% | -4.39% | +30.53% | +94.75% | 18TCr | |
| Average | -0.64% | -2.49% | +22.05% | +73.28% | 37.19TCr | |
| Weighted average by Cap. | -0.68% | -2.11% | +30.30% | +68.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.99Cr 4.44Cr 4.14Cr 3.77Cr 7.12Cr 479.98Cr 7.18Cr 50Cr 19Cr 245.37Cr 19Cr 18Cr 787.49Cr | 6.78Cr 6.02Cr 5.62Cr 5.12Cr 9.66Cr 651.48Cr 9.75Cr 68Cr 26Cr 333.05Cr 25Cr 25Cr 1.07TCr |
| Net income | -6.36Cr -5.65Cr -5.28Cr -4.81Cr -9.07Cr -611.59Cr -9.15Cr -64Cr -25Cr -312.65Cr -24Cr -23Cr -1TCr | -6.02Cr -5.35Cr -4.99Cr -4.55Cr -8.59Cr -578.99Cr -8.67Cr -60Cr -23Cr -295.99Cr -23Cr -22Cr -949.93Cr |
| Net Debt | -7.8Cr -6.93Cr -6.47Cr -5.9Cr -11Cr -749.84Cr -11Cr -78Cr -30Cr -383.33Cr -29Cr -29Cr -1.23TCr | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | $4.490 | +1.13% | 13,19,263 |
| 01/26/01 | $4.440 | -4.10% | 26,86,549 |
| 30/26/30 | $4.630 | -0.86% | 24,12,532 |
| 29/26/29 | $4.670 | -1.68% | 17,08,401 |
| 28/26/28 | $4.750 | +1.50% | 12,76,835 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AQST Stock
Select your edition
All financial news and data tailored to specific country editions
